Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Noveida

- PMLiVE

Access Partnership expands its senior team

Kevin Mayo joins as VP in the US and Pascal King as global director in London

- PMLiVE

Amgen invests $200m in Singapore monoclonal antibody facility

New manufacturing plant will produce both clinical and commercial products

- PMLiVE

Scotland launches £21m fund for rare conditions

Will pay for orphan medicines not recommended by the SMC

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Pharma ‘influencing Polish drug market’

Leads to recommendations for expensive and ineffective medicines says study

- PMLiVE

Government wants Prof David Haslam to be new NICE chair

He would take over from Prof Sir Michael Rawlins in April

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Pharma R&D costs up tenfold since 1970s

Average cost to bring a drug to market now $1.9bn, according to the Office for Health Economics

- PMLiVE

Postcards from China, part 3

Improving market access through integrated solutions

Novartis building

Novartis to issue stark warning to UK at crisis meeting

Says UK needs to address decline in pharma R&D

Drug pricing in Ireland

Sustained pressure on healthcare spending, combined with the continued impact of patent expiries, could thwart the pharma industry in Ireland

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links